Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Survodutide - Boehringer Ingelheim

Next Previous
Drug Profile

Survodutide - Boehringer Ingelheim

Alternative Names: BI-456906; BI-456909

Latest Information Update: 06 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zealand Pharma
  • Developer Boehringer Ingelheim; Zealand Pharma
  • Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides
  • Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-alcoholic steatohepatitis; Obesity
  • Phase II Type 2 diabetes mellitus
  • No development reported Liver cirrhosis

Most Recent Events

  • 17 Feb 2026 Boehringer Ingelheim completes phase-III SYNCHRONIZE™-2 trial for Obesity in the USA, Australia, Belgium, Canada, China, Czech Republic, Denmark, Finland, Germany, Greece, Hungary, Japan, South Korea, Netherlands, New Zealand, Poland, Spain, Sweden and the UK (SC) (NCT06066515)
  • 12 Feb 2026 Boehringer Ingelheim plans a phase I trial in Obesity (In volunteers)the United Kingdom (SC) in March 2026 (NCT07407348)
  • 28 Jan 2026 Boehringer Ingelheim plans a phase I pharmacokinetics trial in Germany (SC) in March 2026 (CTIS2024-519614-30-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top